MedTrace Logo

A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus

NCT01175811 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 402

Last updated 2013-12-18

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to compare the effects on overall glycaemic control of two insulin intensification therapies.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Insulin Lispro Premix

Participant dependent dose, administered subcutaneously for 24 weeks

DRUG

Insulin Glargine

Participant dependent dose, administered subcutaneously for 24 weeks

DRUG

Insulin Lispro

Participant dependent dose, administered subcutaneously for 24 weeks

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • China
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01175811 on ClinicalTrials.gov